<DOC>
	<DOC>NCT01337505</DOC>
	<brief_summary>This is a phase 1b open-label study evaluating the preliminary safety and maximum tolerated dose of a new formulation of INNO-206 administered at doses of 230 mg/m2, 350 mg/m2 and 450 mg/m2 (165, 260, 325 mg/m2 doxorubicin equivalents, respectively) through intravenous infusion on Day 1 every 21 days for up to 6 cycles.</brief_summary>
	<brief_title>Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Age between 18 and 70 years, male or female. Histologically or cytologically confirmed malignant solid tumor that has relapsed or is refractory to standard therapy. Subjects who have received prior radiation therapy with stable CNS metastasis with no progression of brain metastasis by CT/MRI scan in last 4 weeks. Capable of providing informed consent and complying with trial procedures. ECOG performance status 02. Life expectancy &gt;12 weeks. Measurable or evaluable disease according to RECIST 1.1 criteria. Women must not be able to become pregnant (e.g. post menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be nonlactating. Geographic accessibility to the site. Palliative surgery, chemotherapy, immunotherapy and/or radiation less than 4 weeks prior to the Screening Visit. Exposure to any investigational agent within 30 days of the Screening Visit. Laboratory values: Screening serum creatinine greater than or equal to 1.5 mg/dL, alanine aminotransferase (ALT) greater than 3 times the upper limit of normal, total bilirubin greater than 3 times the upper limit of normal, white blood cell (WBC) count &lt; 3500/mm3, absolute neutrophil count &lt; 2000/mm3, platelet concentration &lt; 100,000/mm3, hematocrit level &lt; 33% for females or &lt; 35% for males, or coagulation tests (PT,PTT) &gt;1.5 times the upper limit or normal. Clinically evident congestive heart failure &gt; class II of the New York Heart Association (NYHA) guidelines. Serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V. History or signs of active coronary artery disease with or without angina pectoris. Serious myocardial dysfunction defined scintigraphically (MUGA, myocardial scintigram)or ultrasound determined absolute left ventricular ejection fraction (LVEF) &lt; 45% of predicted. History of HIV infection. Active, clinically significant serious infection requiring treatment with antibiotics, antivirals or antifungals. Major surgery within 3 weeks prior to treatment. Substance abuse or any condition that might interfere with the subject's participation in the study or in the evaluation of the study results. Any condition that is unstable and could jeopardize the subject's participation in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>INNO-206</keyword>
	<keyword>Phase 1</keyword>
	<keyword>DOXO-EMCH</keyword>
	<keyword>Advanced solid tumors</keyword>
</DOC>